1. Home
  2. HLNE vs LEGN Comparison

HLNE vs LEGN Comparison

Compare HLNE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

HOLD

Current Price

$122.99

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$27.80

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLNE
LEGN
Founded
1991
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.9B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
HLNE
LEGN
Price
$122.99
$27.80
Analyst Decision
Hold
Strong Buy
Analyst Count
8
13
Target Price
$159.88
$72.92
AVG Volume (30 Days)
534.0K
1.8M
Earning Date
11-04-2025
11-12-2025
Dividend Yield
1.76%
N/A
EPS Growth
19.80
N/A
EPS
5.55
N/A
Revenue
$733,070,000.00
$909,045,000.00
Revenue This Year
$4.09
$68.68
Revenue Next Year
$19.26
$48.49
P/E Ratio
$22.16
N/A
Revenue Growth
13.01
74.75
52 Week Low
$111.98
$25.71
52 Week High
$196.95
$45.30

Technical Indicators

Market Signals
Indicator
HLNE
LEGN
Relative Strength Index (RSI) 47.32 38.87
Support Level $118.99 $26.43
Resistance Level $125.96 $29.39
Average True Range (ATR) 4.08 1.30
MACD -0.24 -0.11
Stochastic Oscillator 25.57 30.00

Price Performance

Historical Comparison
HLNE
LEGN

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: